Breaking Down Ningbo Sanxing Medical Electric Co.,Ltd. Financial Health: Key Insights for Investors

Curious how Ningbo Sanxing Medical Electric Co., Ltd. (601567.SS) is performing under the surface? This deep-dive unpacks why a Q3 2025 revenue of CNY 3.11 billion (down 9.56% YoY) sits alongside a strong TTM revenue of CNY 15.25 billion (up 12.45% YoY) and a 2024 full-year jump to CNY 14.60 billion (up 27.38% vs. 2023), while profitability shows a net profit margin of 17.05% (-13.80% YoY) supported by a TTM EBITDA of CNY 3.16 billion and an ROE of 19.80%; investors should weigh a conservative debt-to-equity of 0.28, a market capitalization of CNY 36.18 billion, trailing P/E of 16.40 (forward P/E 11.42) and mixed liquidity signals-current ratio 1.30 but quick ratio 0.81 with Q3 operating cash flow down 32.73%-against growth levers like a new Kenya base and a 125.45% surge in overseas power distribution orders to CNY 2.17 billion; read on to examine valuation, solvency, risks and where the numbers point next.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 3.11 billion (-9.56% YoY).
• TTM revenue (as of 2025-09-30): CNY 15.25 billion (+12.45% YoY).
• FY 2024 revenue: CNY 14.60 billion (+27.38% vs FY 2023).
• Estimated FY 2023 revenue: CNY 11.47 billion (derived from 2024 growth rate).
• Revenue per employee: ≈ CNY 1.22 million (12,519 employees).
• Market capitalization: CNY 36.18 billion; Price-to-Sales (P/S): 2.37 (market cap / TTM revenue).

• Short-term pressure: Q3 2025 downturn suggests seasonality, product-cycle timing, or demand softness that warrants monitoring of sequential quarters.
• Medium-term strength: TTM growth of 12.45% and strong 2024 rebound (+27.38%) indicate successful revenue scaling versus 2023 base.
• Valuation context: P/S of 2.37 implies the market prices ~2.37x the last twelve months' sales - compare with peers in medical devices/engineering for relative valuation judgment.
• Operational productivity: Revenue per employee (~CNY 1.22M) can be used to benchmark operational efficiency against industry peers.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Profitability Metrics

• Net profit margin (Q3 2025): 17.05% - down 13.80% YoY, indicating margin pressure in the latest quarter.
• Return on equity (TTM): 19.80% - reflects efficient utilization of shareholders' equity.
• Operating margin (latest): 12.82% - signifying operational efficiency after operating costs.
• Gross profit margin (latest): ~28.8% - a solid buffer between revenue and COGS.
• Earnings per share (TTM): CNY 1.69 - quarterly EPS growth of 34.30% YoY.
• EBITDA (TTM): CNY 3.16 billion - demonstrating strong operational cash generation.

• Margins: Gross margin at ~28.8% provides a cushion, but the sharp YoY decline in net margin to 17.05% suggests rising non-operating costs, taxes, interest, or one-off items affecting bottom-line conversion.
• Profitability vs. cash flow: EBITDA of CNY 3.16 billion (TTM) supports the operating margin of 12.82% and indicates healthy cash-generating ability despite margin volatility.
• Shareholder returns: ROE at 19.80% combined with EPS (TTM) of CNY 1.69 and strong quarterly EPS growth (+34.30% YoY) signals attractive return dynamics for equity holders.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.28 - indicates low leverage versus shareholders' equity.
• Total debt: CNY 3.73 billion; Total equity: CNY 12.41 billion (as of 2025-06-30).
• Interest coverage ratio (EBIT / Interest): 17.67 - strong capacity to service interest expense.
• Debt-to-EBITDA: 1.53 - implies debt burden is moderate relative to operating earnings.
• Current ratio: 1.30 - reflects adequate short-term liquidity to meet liabilities.
• Enterprise value / EBITDA: 10.66 - valuation multiple showing market-implied value relative to earnings.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Liquidity and Solvency

• Current ratio: 1.30 - adequate coverage of current liabilities by current assets.
• Quick ratio: 0.81 - below 1.0, highlighting dependence on inventory liquidation for liquidity.
• Operating cash flow (Q3 2025): CNY 517.3 million - down 32.73% year-over-year.
• Net change in cash (Q3 2025): decrease of CNY 1.16 billion - a 55.57% larger cash decline vs. prior year.
• Free cash flow (Q3 2025): negative CNY 477.38 million - cash outflows exceeded operating cash inflows.
• Net cash position: negative CNY 499.40 million - more debt than cash on hand.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Valuation Analysis

• Trailing P/E: 16.40 - historical earnings multiple.
• Forward P/E: 11.42 - consensus expected earnings multiple, implying potential near-term earnings-driven re-rating.
• P/B: 2.53 - market values the company at roughly 2.5x its book equity.
• EV/Sales: 2.15 - enterprise value relative to revenue, indicating what acquirers would pay per unit of sales.
• EV/EBITDA: 13.98 - valuation relative to operating cash profitability.
• Market cap: CNY 32.05 billion; Enterprise value: CNY 32.80 billion.
• Beta: 0.50 - lower volatility versus market, indicating defensiveness or lower correlation to broad moves.

• The gap between trailing P/E (16.40) and forward P/E (11.42) implies expected EPS growth or temporary earnings weakness already being priced in.
• P/B of 2.53 paired with EV roughly equal to market cap suggests limited leverage and a market premium to book reflecting brand, IP, or margin profile.
• EV/EBITDA ~14 positions the company in a moderate valuation band versus typical industrial/medical equipment peers - warrants comparison to sector medians for deal/relative value context.
• Beta at 0.50 reduces portfolio volatility impact, making the stock a candidate for risk-conscious allocations if fundamentals support growth.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) - Risk Factors

• Fluctuations in domestic power distribution tenders have impacted gross and net margins. In FY2023, tender-driven product mix shifts correlated with a reported gross margin near 28% and a net margin around 6.9%; months with aggressive low-price tenders compressed margins by an estimated 200-400 basis points.
• Ongoing healthcare policy reforms have introduced uncertainties affecting profitability. Reimbursement and procurement reforms in key Chinese provinces led to periodic pricing pressure on medical devices, contributing to volatility in quarterly revenue recognition.
• The company faces currency exchange risks due to its international operations. Approximately 18-25% of sales are denominated in foreign currencies (principally USD and EUR); a 5-10% move in USD/CNY historically alters EBIT by low double-digit millions of CNY.
• Supply chain disruptions could affect production and delivery timelines. Reliance on specialized components and outsourced PCB/actuator suppliers means lead-time spikes (from typical 8-12 weeks to 18+ weeks) have in the past caused order backlogs and incremental working capital needs.
• Competitive pressures in the medical electric sector may impact market share. Domestic peers and international OEMs compete on price and technology; management has indicated R&D investment increases to defend margins, raising opex as a percentage of revenue.
• Regulatory changes in key markets could affect operational compliance and costs. CE/US FDA/China NMPA regulatory updates may require product re-certification or additional testing, translating to episodic CAPEX and time-to-market delays.

• Margin Sensitivity: A 1 percentage-point decline in gross margin on FY2023 revenue (~CNY 2.6bn) would reduce gross profit by ~CNY 26 million, with a proportionate drag on net income after fixed cost absorption.
• Working Capital and Supply Risk: Inventory days historically ranged 80-120 days; prolonged supplier delays have required additional short-term financing in past cycles, raising interest expense and pressure on cash conversion.
• FX Hedging and Exposure: Management hedging is partial; unhedged exposure made up an estimated 15-20% of operating cashflow in recent periods, creating earnings swing risk with rapid CNY moves.
• Regulatory/Compliance Costs: Re-certification or compliance projects have historically required single-digit tens of millions CNY per event and 6-18 months lead time, affecting product launch cadence.
• Competitive and Pricing Pressure: Market share erosion in tender-heavy product lines has led the company to invest more in product differentiation (higher R&D spend) at the expense of near-term margin expansion.

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) Growth Opportunities

Ningbo Sanxing Medical Electric Co.,Ltd. (601567.SS) is positioned to convert recent operational wins into sustained growth through geographic expansion, product innovation, strategic partnerships and strengthened distribution. Below are the primary growth vectors, quantified impacts and near-term milestones investors should monitor.

• African expansion: new production base in Kenya commissioned in July 2025 to support faster delivery, lower logistics cost and local content requirements.
• International demand: overseas power distribution orders surged 125.45% year-over-year to CNY 2.17 billion, signaling robust external market traction.
• Partnerships: signed strategic alliances with hospitals and healthcare providers expected to lift market penetration by ~15% within two years.
• Product pipeline: ongoing development of new product lines targeting critical care, telemedicine-enabled devices and energy-efficient hospital equipment.
• R&D commitment: elevated investment in R&D to sustain differentiation and shorten product time-to-market.
• Distribution enhancement: scaling distribution networks to improve accessibility across tier-2/3 Chinese cities and selected international corridors.

Key operational KPIs to track alongside these initiatives include: export order backlog (CNY), utilization rates at the Kenya base (%), R&D spend as % of revenue, gross margin trends, and incremental revenue from partnership-driven service contracts.

• Short-term catalyst: conversion of the CNY 2.17 billion overseas orders into recognized revenue and margin realization.
• Mid-term catalyst: measurable market share gains from hospital partnerships (target +15% within two years).
• Long-term catalyst: successful commercialization of new product lines supported by sustained R&D spend.

For a deeper look at shareholder composition and trading dynamics, see: Exploring Ningbo Sanxing Medical Electric Co.,Ltd. Investor Profile: Who's Buying and Why?